

Day 3 May 21 (Fri.)

Plenary Session Scientific Program Educational Session Free Papers(Oral) Social Event E English Session Web Live-Stream Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Kyoto International Conference Center	Room 01	Main Hall (1F)	Web New Guideline 01 Clinical management of myotonic dystrophy evolving from guideline					LS-26 Sumitomo Dainippon Pharma Co., Ltd.	Web VPr Vice President Lecture	Web Symposium 33 Gender Equality of the World's Top Scientists							
	Room 02	Annex Hall 1 (1F)	Symposium 26 Development of an algorithm for the diagnosis of encephalitis/ meningitis. Crosstalk between infectious disease and autoimmune encephalitis		O-25 Neuroinfection			LS-27 Alexion Pharma GK		History Session The interesting history of neurology							
	Room 03	Annex Hall 2 (1F)	LM-07 Lecture Marathon 07	LM-08 Lecture Marathon 08	O-26 Dementia3			LS-28 Mitsubishi Tanabe Pharma Corporation		LM-09 Lecture Marathon 09	LM-10 Lecture Marathon 10						
	Room 04	Room A (2F)	Web Hot Topics 07 Innovative management can bring bright future for Parkinson's disease		O-27 Parkinsonism and Related disorders 4			LS-29 Eisai Co., Ltd.	Web SPL-02 Semi-Plenary Lecture 02	Web SL-01 Special Lecture 01							
	Room 05	Room B-1 (2F)	Web Symposium 27 Neurologic Specialty Board in the World		O-28 Neuroscience 2			LS-30 SHINO-TEST CORPORATION	Web SPL-03 Semi-Plenary Lecture 03	Web Neuroscience Frontier Symposium 04 Structure and propagation of aggregated proteins				ES-04 Eisai Co., Ltd.			
	Room 06	Room B-2 (2F)	Web Symposium 28 Novel therapeutic strategies against ischemic stroke from the perspective of neuro-glial-vascular unit		O-29 Clinical trial and Regenerative medicine 2			LS-31 Japan Blood Products Organization		Web Symposium 34 Increasing importance of autonomic neuroscience in multiple system atrophy							
	Room 07	Room D (1F)	Symposium 29 Multidisciplinary approach in mechanism of epilepsy: contribution of glia and neuron		O-30 Epilepsy 2			LS-32 Medtronic Japan Co., Ltd.		Web Symposium 35 Disassemble "CIDP"! Reclassification of "CIDP" based on molecular autoimmune mechanism				ES-05 Amgen K.K. Medical Affairs			
	Room 08	Room E (1F)	Symposium 30 How to neurophysiologically analyze pathomechanisms underlying neurological disorders		O-31 Clinical Neurophysiology 3			LS-33 Bayer Yakuhin, Ltd.		Symposium 36 Internationalization - Where should we head to?				ES-06 GlaaxoSmithKline K.K.			
	Room 09	Sakura Hall (1F)	Symposium 31 Exploring ESUS ~ New Developments in Search for Embolic Sources and Treatment ~		O-32 Cerebrovascular disease 4			LS-34 AbbVie GK		Symposium 37 Importance of pathological confirmation diagnosis for clinical return							
	Room 10	Swan Hall (1F)	Symposium 32 Topics and new approach to patients with higher cerebral dysfunction		O-33 Neuroimmunology 3			LS-35 Bristol-Myers Squibb / Pfizer Japan Inc.		Symposium 38 Can complex systems, AI, and big data reveal the missing link in the elucidation of the pathophysiology of neurodegenerative diseases?							
	Room 11	Room 157 (1F)	LB Late Breaking Symposium		O-34 Neurogenetics and Gene therapy			LS-36 argenx Japan K.K.		Symposium 39 Disaster medical system for the patients with the intractable neurological diseases: past, present, and future							
	Room 12	Room C-1 (1F)			O-35 Parkinsonism and Related disorders 5			LS-37 CHUGAI PHARMACEUTICAL CO., LTD.									
	Room 13	Room C-2 (1F)			O-36 Cerebellar ataxia and Myelopathy 2			LS-38 Novartis Pharma K.K. Medical Division									
	Room 14	Room 553 (5F)			O-37 Peripheral neuropathy and Metabolic disorders 1												
Poster Session	New Hall (1F)		Poster Preparation / Poster Viewing				Poster Discussion	Poster Viewing				Poster Discussion	Poster Removal				

DAY 3